Barclays’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $107 | Buy |
+14
| New | +$148 | ﹤0.01% | 5189 |
|
|
2023
Q4 | – | Sell |
-279
| Closed | -$10.5K | – | 5240 |
|
|
2023
Q3 | $10.5K | Buy |
+279
| New | +$16K | ﹤0.01% | 4295 |
|
|
2022
Q3 | – | Sell |
-8
| Closed | – | – | 4846 |
|
|
2022
Q2 | $0 | Sell |
8
-327
| -98% | -$15K | ﹤0.01% | 5067 |
|
|
2022
Q1 | $22K | Sell |
335
-2,168
| -87% | -$155K | ﹤0.01% | 4418 |
|
|
2021
Q4 | $210K | Buy |
2,503
+1,645
| +192% | +$185K | ﹤0.01% | 3548 |
|
|
2021
Q3 | $140K | Buy |
858
+561
| +189% | +$91.2K | ﹤0.01% | 3769 |
|
|
2021
Q2 | $45K | Sell |
297
-1,420
| -83% | -$239K | ﹤0.01% | 4176 |
|
|
2021
Q1 | $299K | Buy |
1,717
+1,054
| +159% | +$201K | ﹤0.01% | 3500 |
|
|
2020
Q4 | $105K | Sell |
663
-277
| -29% | -$46.4K | ﹤0.01% | 4109 |
|
|
2020
Q3 | $150K | Sell |
940
-1
| -0.1% | -$180 | ﹤0.01% | 4028 |
|
|
2020
Q2 | $185K | Buy |
941
+435
| +86% | +$79.9K | ﹤0.01% | 4123 |
|
|
2020
Q1 | $77K | Sell |
506
-1,025
| -67% | -$103K | ﹤0.01% | 4963 |
|
|
2019
Q4 | $118K | Buy |
1,531
+773
| +102% | +$67.4K | ﹤0.01% | 5380 |
|
|
2019
Q3 | $76K | Sell |
758
-229
| -23% | -$26.6K | ﹤0.01% | 5677 |
|
|
2019
Q2 | $130K | Sell |
987
-63
| -6% | -$8.66K | ﹤0.01% | 5480 |
|
|
2019
Q1 | $159K | Buy |
1,050
+370
| +54% | +$57.6K | ﹤0.01% | 4996 |
|
|
2018
Q4 | $109K | Buy |
680
+76
| +13% | +$15.1K | ﹤0.01% | 4985 |
|
|
2018
Q3 | $155K | Buy |
604
+489
| +425% | +$123K | ﹤0.01% | 5197 |
|
|
2018
Q2 | $27K | Sell |
115
-261
| -69% | -$49.4K | ﹤0.01% | 6015 |
|
|
2018
Q1 | $53K | Sell |
376
-1,284
| -77% | -$194K | ﹤0.01% | 5864 |
|
|
2017
Q4 | $216K | Buy |
+1,660
| New | +$211K | ﹤0.01% | 4619 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6865 |
|
|
2017
Q2 | – | Sell |
-128
| Closed | -$11.2K | – | 6676 |
|
|
2017
Q1 | $11K | Buy |
128
+125
| +4,167% | +$14K | ﹤0.01% | 6038 |
|
|
2016
Q4 | $0 | Buy |
+3
| New | +$328 | ﹤0.01% | 6631 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6626 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6359 |
|
|
2015
Q3 | – | Sell |
-113
| Closed | -$14K | – | 6854 |
|
|
2015
Q2 | $14K | Buy |
+113
| New | +$15.4K | ﹤0.01% | 5880 |
|
Other funds holding CTSO
CM
Barclays's CTSO Position: Q2 2026 in Review
Barclays opened a new position in Cytosorbents Corp (CTSO) in Q2 2026: 14 shares worth $107. The stake represents ﹤0.01% of the portfolio and ranks #5189 among its holdings. This is a return to the name: Barclays previously reported a position in CTSO as recently as Q3 2023.
Barclays first reported a position in CTSO in Q2 2015 and has held it in 24 quarters since. The position peaked at $299K in Q1 2021. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- Barclays held 14 shares of Cytosorbents Corp worth $107 as of Q2 2026.
- Cytosorbents Corp was a new Barclays position in Q2 2026.
- Cytosorbents Corp made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5189 holding.
- Barclays first reported a position in Cytosorbents Corp in Q2 2015 and has held it in 24 quarters since.
- Barclays's Cytosorbents Corp position peaked at $299K in Q1 2021.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.